Chan Hiok Hong, Wong Tina T, Lamoureux Ecosse, Perera Shamira
*Yong Loo Lin School of Medicine, National University of Singapore †Singapore National Eye Centre ‡Singapore Eye Research Institute ∥Duke-NUS Graduate Medical School, Singapore, Republic of Singapore §Centre for Eye Research Australia, University of Melbourne, Royal Victorian Eye and Ear Hospital, Melbourne, Vic, Australia.
J Glaucoma. 2015 Sep;24(7):485-92. doi: 10.1097/IJG.0000000000000197.
To investigate the acceptance and preferences rates of 3 sustained drug delivery systems in glaucoma patients.
A cross-sectional study involving 250 Chinese patients recruited from outpatient glaucoma clinics in Singapore using an interviewer-administered survey. Beliefs toward medicines, eye drops, illness perception, medication adherence, and health literacy were assessed using validated questionnaires. After receiving standard information on the 3 sustained drug delivery systems, that is, subconjunctival, intracameral, and punctal routes; each route's acceptance and attitudes were determined.
The subconjunctival (acceptance: 61.6%, n=154), intracameral (acceptance: 57.2%, n=143), and punctal (acceptance: 63.2%, n=158) routes were willing to be accepted by the majority of the interviewed patients. Among those, 78.6%, 79.1%, and 78.5% were willing to pay an equal or higher cost compared with their current eye drops for the subconjunctival, intracameral, and punctal plug routes, respectively. Independent factors associated with the acceptance for subconjunctival, intracameral, and punctal plug routes included: male sex (P=0.007, 0.014, 0.046, respectively), patients not on health care subsidies (P=0.022, 0.002, 0.016, respectively), and bilateral glaucoma disease (P=0.003, 0.013, 0.004, respectively). A total of 120 (48.0%) patients ranked punctal plug placement as the preferred route for sustained drug delivery followed by subconjunctival (n=76, 30.4%) and intracameral (n=54, 21.6%) routes.
Sustained drug delivery for the medical treatment of glaucoma is an acceptable alternative to daily eye drop administration by most Singaporean Chinese individuals in this study. Male patients, nonsubsidized patients, and those with bilateral glaucoma were independently associated with preference of these 3 alternative routes of administration to traditional glaucoma drops.
研究青光眼患者对3种药物缓释系统的接受率和偏好率。
一项横断面研究,通过访员实施的调查,从新加坡门诊青光眼诊所招募了250名中国患者。使用经过验证的问卷评估对药物、眼药水的看法、疾病认知、用药依从性和健康素养。在收到关于3种药物缓释系统(即结膜下、前房内和泪小点途径)的标准信息后,确定每种途径的接受情况和态度。
结膜下途径(接受率:61.6%,n = 154)、前房内途径(接受率:57.2%,n = 143)和泪小点途径(接受率:63.2%,n = 158)愿意被大多数受访患者接受。其中,分别有78.6%、79.1%和78.5%的患者愿意为结膜下、前房内和泪小点塞途径支付与他们目前眼药水相同或更高的费用。与结膜下、前房内和泪小点塞途径接受度相关的独立因素包括:男性(分别为P = 0.007、0.014、0.046)、未享受医疗补贴的患者(分别为P = 0.022、0.002、0.016)和双侧青光眼疾病(分别为P = 0.003、0.013、0.004)。共有120名(48.0%)患者将泪小点塞放置列为药物缓释的首选途径,其次是结膜下途径(n = 76,30.4%)和前房内途径(n = 54,21.6%)。
在本研究中,对于大多数新加坡华裔个体而言,药物缓释用于青光眼治疗是日常滴眼剂给药的可接受替代方法。男性患者、未享受补贴的患者以及双侧青光眼患者独立地与这3种替代给药途径优于传统青光眼滴眼液的偏好相关。